Pharmafile Logo
Pharmafocus logo
Advanced Search

lung cancer

Showing 15 posts of 186 posts found.

bmssyracuseny

BMS’ Opdivo+Yervoy combo fails in small cell lung cancer

November 27, 2018
Manufacturing and Production, Research and Development Bristol-Myers Squibb, Cancer, Yervoy, lung cancer, opdivo, pharma

Bristol-Myers Squibb has revealed that its combo comprising Opdivo (nivolumab) and Yervoy (ipilimumab) failed to meet its primary endpoint as …

News
astrazeneca_sign_sky

AstraZeneca’s Imfinzi immunotherapy combo fails to show benefit in lung cancer

November 16, 2018
Medical Communications, Research and Development AstraZeneca, Cancer, Imfinzi, lung cancer, pharma

AstraZeneca has revealed that its immunotherapy combo of Imfinzi (durvalumab) and tremelimumab failed to meet its primary endpoint in a …

News
merckincweb2

MSD’s Keytruda/chemo combo scores first-line FDA approval in NSC lung cancer

November 1, 2018
Sales and Marketing Cancer, MSD, NSCLC, keytruda, lung cancer, pharma

MSD’s blockbuster anti-PD-1 immunotherapy has secured another FDA approval, it has emerged, in combination with carboplatin and either paclitaxel or …

News
roche

Roche’s Alecensa topples Pfizer’s Xalkori in Asian patients with ALK+ advanced lung cancer

October 23, 2018
Manufacturing and Production, Research and Development Alecensa, Cancer, ESMO 2018, Roche, lung cancer, pharma

Following up on the reveal of data concerning its immunotherapy Tecentriq in combination with chemotherapy in the treatment of non-small …

News

BMS’ Opdivo fails to improve overall survival in small-cell lung cancer

October 15, 2018
Research and Development, Sales and Marketing BMS< Opdivo, Bristol-Myers Squibb, Cancer, lung cancer, pharma

Bristol-Myers Squibb’s Opdivo (nivolumab) failed to deliver on its primary endpoint in a Phase 3 study in small-cell lung cancer, …

News

Roche’s Tecentriq+chemo combo shows first-line benefit in small cell lung cancer

September 26, 2018
Research and Development Cancer, Combo, Roche, chemotherapy, lung cancer, pharma, tecentriq

Roche has unveiled new Phase 3 data for its cancer immunotherapy Tecentriq (atezolizumab) in combination with carboplatin and etoposide chemotherapy …

News
astrazeneca_building_white

AstraZeneca chalks up European approval for Imfinzi in locally advanced, unresectable lung cancer

September 25, 2018
Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MedImmune, NSCLC, lung cancer, pharma

AstraZeneca and its global biologics R&D arm MedImmune have announced the approval by the European Commission of Imfinzi (durvalumab) as …

News
merckentranceweb

Keytruda scores ground-breaking European approval in lung cancer subgroup

September 10, 2018
Sales and Marketing Cancer, EU, Europe, MSD, Merck, NSCLC, keytruda, lung cancer, pharma

Keytruda (pembrolizumab) has chalked up yet another approval for MSD, this time in Europe in combination with permextred and platinum-based …

News
astrazeneca_sign_sky

Japan approves AstraZeneca’s Tagrisso in EGFRm non-small cell lung cancer

August 21, 2018
Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, Japan, Tagrisso, lung cancer, pharma

AstraZeneca has revealed that its EGFR tyrosine kinase inhibitor Tagrisso (osimertinib) has been approved in Japan by the nation’s Ministry …

News
Image Credit: Bristol-Myers Squibb

FDA approves Bristol Myers Squibb’s Opdivo in small-cell lung cancer

August 20, 2018
Sales and Marketing Bristol-Myers Squibb, FDA, approval, bristol myers squibb, lung cancer, opdivo

The FDA has approved Bristol Myers Squibb’s Opdivo (nivolumab) for patients with metastatic small-cell lung cancer (SCLC), as the first …

News

Chinese regulators approve Roche’s Alecensa in regulatory shift

August 20, 2018
Sales and Marketing Cancer, China, Roche, approval, lung cancer

China’s National Drug Administration has granted rapid approval for Roche’s lung cancer treatment Alecensa (alectinib). Chinese regulators have in the …

News
3922609891_dced293244_z

Rare lung cancer drug approved in Scotland

August 14, 2018
Manufacturing and Production Cancer, SMC, Scotland, Scottish Medicines Consortium, approval, lung cancer

The Scottish Medicines Consortium has approved Roche’s cancer drug alectinib for the treatment of patients with untreated advanced non-small-cell lung …

News
takeda_usa_pharmaceuticals_u

Takeda’s Alunbrig topples Pfizer’s Xalkori in ALK-positive lung cancer

July 27, 2018
Medical Communications, Research and Development Alunbrig, Cancer, NSCLC, Pfizer, Takeda, Xalkori, lung cancer, pharma

Takeda has unveiled new Phase 3 data showing that its tyrosine kinase inhibitor (TKI) Alunbrig (brigatinib) not only met its …

News
astrazeneca-sign

AstraZeneca chalks up double Japanese approval in lung and breast cancer

July 2, 2018
Sales and Marketing AstraZeneca, Cancer, Imfinzi, NSCLD, breast cancer, lung cancer, lynparza, pharma

It’s a big step forward for AstraZeneca’s global marketing operations as the company announced that two of its products have …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

June 29, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HIV, J&J, JJ, Remicade, Roche, biosimilar Amgen, lung cancer, multiple sclerosis, pharma

Summer seems to be in full swing as we reach the end of June, so it’s time to look back …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023